Thelansis

Asthma Emerging Therapy and TPP Insights Thelansis’s “Asthma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes and levels Physician like...

Asthma Epidemiology Insights Thelansis’s “ ⁠ Asthma Epidemiology Insights and Forecast Report – 2020 To 2040 ″  provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies. Key business questions answered: 20-year historical and forecast data (2020–2040) Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes) Granular patient population coverage by year and geography Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc. Patient funnels ...

Asthma Epidemiology Insights Thelansis’s “ ⁠ Asthma Epidemiology Insights and Forecast Report – 2020 To 2040 ″  provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies . Asthma Overview Asthma is a chronic inflammatory airway disease characterised by variable, reversible airflow obstruction, bronchial hyperresponsiveness, and airway remodelling, driven predominantly by Th2-mediated eosinophilic inflammation — with type 2 cytokines IL-4, IL-5, and IL-13 central to its pathobiology — alongside non-eosinophilic neutrophilic and mixed ...

Asthma Emerging Therapy and TPP Insights Thelansis’s “Asthma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Asthma Overview Asthma is a chronic inflammatory airway disease characterised by variable, reversible airflow obstruction, bronchial hyperresponsiveness, and airway remodelling, driven predominantly by Th2-mediated eosinophilic inflammation — with type 2 cytokines IL-4, IL-5, and IL-13 central to its pathobiology — alongside non-eosinophilic neutrophilic and mixed phenotypes recognising asthma’s considerable biological heterogeneity. Genetic susceptibility, allergen sensitisation, respiratory viral infections, occupational exposures, and obesity interact as key disease determinants. Patients present with episodic wheeze, dyspnoea...

Asthma Market Access and Reimbursement Insights Thelansis’s “Asthma Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Asthma Overview Asthma is a chronic inflammatory disease of the airways characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, caused by airway hyperresponsiveness and narrowing often triggered by allergens, infections, exercise, smoke, or environmental irritants. Affecting hundreds of millions of people worldwide, asthma is diagnosed based on clinical history, physical examination, and lung function tests, such as spirometry. It is commonly classified into sever...

Asthma Emerging Therapy and TPP Insights Thelansis’s “Asthma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Asthma Overview Asthma is a chronic inflammatory disease of the airways characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, caused by airway hyperresponsiveness and narrowing often triggered by allergens, infections, exercise, smoke, or environmental irritants. Affecting hundreds of millions of people worldwide, asthma is diagnosed based on clinical history, physical examination, and lung function tests, such as spirometry. It is commonly classified into several types: allergic, non-allergic, occupational, and exercise-induced. The management focuses on controlling symptoms and...

Asthma Market Access and Reimbursement Insights Thelansis’s “Asthma Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve market access Pricing, etc. Impact on br...

Asthma Emerging Therapy and TPP Insights Thelansis’s “Asthma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes and levels ...

Asthma Market Outlook Thelansis’s “Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Asthma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do interviewed experts p...

Asthma Market Outlook Thelansis’s “Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Asthma     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Asthma Overview Asthma represents a multifaceted clinical syndrome characterized by variable airflow obstruction, bronchial hyperresponsiveness (BHR), and cellular inflammation. The Global Initiative for Asthma (GINA) defines asthma as a heterogeneous disease primarily marked by airway inflammation. The presence of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough, exhibiting variability over time and in intensity, alongside variable expira...

 Asthma represents a multifaceted clinical syndrome characterized by variable airflow obstruction, bronchial hyperresponsiveness (BHR), and cellular inflammation. The Global Initiative for Asthma (GINA) defines asthma as a heterogeneous disease primarily marked by airway inflammation. The presence of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough, exhibiting variability over time and in intensity, alongside variable expiratory airflow limitation, constitutes the defining features of asthma. This condition results in fluctuating respiratory symptoms and variable airflow limitation, culminating in compromised activity levels, diminished quality of life, and occasional exacerbations, colloquially termed 'asthma attacks.' These exacerbations may necessitate emergency healthcare utilization and hospitalization and, in rare instances, lead to fatalities. Asthma's risk factors encompass genetic, environmental, and host-related elements. Whil...

  Asthma is a chronic inflammatory condition of the airways in which hypertrophy of bronchial smooth muscle and mucous glands with plugging of small airways with thick mucus can occur. This airway inflammation contributes to airway hyper-responsiveness, airflow limitation, and respiratory symptoms and is at the root of the disease's chronic nature. Based on the clinical features classified as mild intermittent, mild persistent, moderate persistent, or severe persistent, depending on symptom frequency and severity and lung function as assessed by forced expiratory volume in 1 second (FEV1). Depending on symptoms, signs, and functional assessment, asthma exacerbations are classified as mild, moderate, severe, and impending respiratory failure. The incidence of Asthma in the USA varies from 158 to 187 cases per 100,000 populations, and the prevalence varies between 6.7 to 8.5 across all ages. Thelansis’s “Asthma Market Outlook, Epidemiology, Competitive Landscape , an...

  Asthma is a chronic inflammatory condition of the airways in which hypertrophy of bronchial smooth muscle and mucous glands with plugging of small airways with thick mucus can occur. This airway inflammation contributes to airway hyper-responsiveness, airflow limitation, and respiratory symptoms and is at the root of the disease's chronic nature. Based on the clinical features classified as mild intermittent, mild persistent, moderate persistent, or severe persistent, depending on symptom frequency and severity and lung function as assessed by forced expiratory volume in 1 second (FEV1). Depending on symptoms, signs, and functional assessment, asthma exacerbations are classified as mild, moderate, severe, and impending respiratory failure. The incidence of Asthma in the USA varies from 158 to 187 cases per 100,000 populations, and the prevalence varies between 6.7 to 8.5 across all ages The competitive landscape of Asthma includes country-specific approved and pipeline therap...